How to buy Johnson & Johnson (JNJ) stock from India

Yes, an Indian resident can buy Johnson & Johnson — legally, in US dollars, under the RBI's Liberalised Remittance Scheme (LRS). JNJ trades on NYSE. It pays a quarterly dividend (~3% yield). Post-Kenvue spin-off (May 2023), JNJ is a pure pharmaceutical and medical technology company — one of the world's largest. It has raised its dividend for 62 consecutive years, earning Dividend King status. For Indian investors who want defensive healthcare exposure with income, JNJ is the anchor holding.

The 30-second version

• Legal and simple. Buy JNJ via Vested, INDmoney, or Interactive Brokers India.
• Quarterly dividend (~3% yield). File Form W-8BEN for 15% DTAA withholding; claim FTC via Form 44.
• India tax on gains: hold more than 24 months → 12.5% LTCG (Section 112); shorter hold → slab rate.
• Estate-tax trap: US-situs asset — above $60,000 of total US-situs assets, up to 40% US estate tax, no treaty relief.
• The positioning: JNJ is the defensive healthcare core — 62 years of dividend growth, AAA credit rating, diversified across oncology, immunology, neuroscience, and medtech. It does not have LLY's GLP-1 upside or NVO's innovation excitement. It is the healthcare holding that keeps paying you through every market cycle.

Quick facts

Can an Indian resident buy it?	Yes — fully legal under the LRS
Ticker / exchange	JNJ / NYSE
How	IBKR, Rovia, INDmoney, or Vested
Minimum	A fraction of one share
Dividend	~$1.24/quarter (~3% annual yield)
India tax on gains	12.5% LTCG after 24 months; else your slab (Section 112)
Dividend tax	15% US WHT (DTAA) + Indian slab; FTC via Form 44
Estate-tax risk	US-situs above $60k → up to 40%, no treaty relief
Annual compliance	Schedule FA + dividend disclosure every year

How to buy it — 3 steps

1. Open an account and finish KYC. Use IBKR for the widest access and best execution, Rovia for a combined RSU + LRS experience, or INDmoney / Vested for a simple India-funded flow. File Form W-8BEN during onboarding.
2. Fund via the LRS. Cap: $250,000/year. 20% TCS above ₹7 lakh — creditable against income tax.
3. Place the order. JNJ is one of the most liquid NYSE stocks. Market orders work. JNJ reports quarterly — key metrics are pharmaceutical sales growth (especially Darzalex and oncology pipeline), MedTech segment margins, and any Kenvue holding disposition updates.

What Johnson & Johnson actually is (post-Kenvue)

Pharmaceutical (~55% of revenue):

• Oncology: Darzalex (multiple myeloma) — one of the world's best-selling cancer drugs, growing strongly; Erleada (prostate cancer); Rybrevant (lung cancer)
• Immunology: Tremfya (psoriasis, IBD); Stelara (psoriasis, Crohn's disease) — facing biosimilar competition from 2025
• Neuroscience: Spravato (treatment-resistant depression) — growing rapidly as the first new depression treatment mechanism in decades
• Infectious disease: Vaccines and antiretroviral drugs

MedTech (~45% of revenue):

• Orthopedics (DePuy Synthes): Hips, knees, spine — global leader in orthopedic implants
• Cardiovascular (Abiomed): Heart pumps (Impella) and cardiovascular devices
• Surgery: Ethicon (surgical instruments, sutures) and advanced robotic surgery systems
• Vision: Contact lenses and cataract surgery equipment (acquired Abbott Medical Optics)

The Talc litigation: JNJ has been working to resolve decades-long talc-related lawsuits (alleging asbestos contamination causing cancer) through a subsidiary bankruptcy process. This legal liability has been an overhang on the stock — resolution is the catalyst to watch.

The AAA credit rating: JNJ is one of only two US companies (with Microsoft) to hold an AAA credit rating from S&P — the highest possible. This reflects 62 years of dividend growth and exceptional balance sheet management.

The tax that actually matters

On capital gains:

Holding period	Treatment	Rate
24 months or less	Short-term	Your slab rate
More than 24 months	Long-term	12.5%, no indexation

On quarterly dividend: US withholds 15% (with W-8BEN filed); balance at Indian slab; claim FTC via Form 44.

Full rules: how US stocks are taxed in India.

The $60,000 estate-tax trap

Directly-held JNJ is a US-situs asset. Above $60,000 of total US-situs holdings at death, US estate tax of up to 40% — no India-US treaty protection. See the estate-tax trap guide.

JNJ vs LLY vs MRK — pharma positioning

If you want…	Best route
Defensive healthcare core, 62-year dividend streak	JNJ
GLP-1 obesity and diabetes innovation leader	LLY (Eli Lilly)
Oncology + Keytruda (best-selling cancer drug)	MRK (Merck)
Full pharma and GLP-1 picture	Pharma and GLP-1 stocks guide for Indian investors